Aurobindo Pharma Ltd gets 3 observations from USFDA for Unit 3 at Bachupally Village

The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma Limited's Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana, from 14th July to 21st July 2023.

At the end of the inspection, we have been issued a 'Form 483' with 3 observations. The observations are procedural in nature. We will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observations at the earliest.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 779.40 as compared to the previous close of Rs. 772.35. The total number of shares traded during the day was 49634 in over 3034 trades.

The stock hit an intraday high of Rs. 791.50 and intraday low of 771.65. The net turnover during the day was Rs. 38790730.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 USFDA Inspection Unit3 Formulation ManufacturingFacility Form483 3Observations